anlotinib  (MultiTarget Pharmaceuticals)

Journal: eBioMedicine

Article Title: Multimodal data integration for biologically-relevant artificial intelligence to guide adjuvant chemotherapy in stage II colorectal cancer

doi: 10.1016/j.ebiom.2025.105789

Figure Lengend Snippet: Preclinical imaging analysis . ( a ) Flowchart of vessel maturity treatment and CT imaging. ( b ) The growth curves for mouse models receiving no treatment (control) and anlotinib treatment. ( c ) Representative images of contrast-enhanced CT images for in control (left) and anlotinib-treated groups (right). ( d ) Immunofluorescent double staining for CD31 (endothelial marker, green) and α-SMA (vascular smooth muscle cell marker, red) of sections of tumour samples in control (left) and anlotinib-treated groups (right). ( e ) The eight selected radiomic features with significant differences in control (left, n = 6) and anlotinib-treated groups (right, n = 6). P values were derived from the Mann–Whitney U tests. ( f ) Schematic of the mechanisms by which heterogeneous morphology of tumour vessels in artificial intelligence-based radiological subtypes leads to different survival benefit from adjuvant chemotherapy for patients with stage II colorectal cancer. Abbreviations: α-SMA, a-smooth muscle actin. Created with BioRender.com .

Article Snippet: Anlotinib, a multitarget antiangiogenic tyrosine kinase inhibitor, reported to significantly affect vascular patterns of sensitizing non-angiogenic tumours to chemotherapy, was used for the modification of vascular patterns in mouse models.

Techniques: In Vivo Imaging, Imaging, Control, Double Staining, Marker, Derivative Assay, MANN-WHITNEY, Adjuvant